GADD45A: A Potential Drug Target and Biomarker (G1647)

Target Name: GADD45A

NCBI ID: G1647

GADD45A

GADD45A: A Potential Drug Target and Biomarker

GADD45A, also known as GAD67, is a gene that encodes for a protein involved in the intracellular signaling pathway known as the G-protein-coupled receptor (GPCR) signaling pathway. This pathway is involved in the regulation of various cellular processes, including inflammation, stress response, and neurotransmission. GADD45A has been identified as a potential drug target and biomarker for various diseases, including mental health, addiction, and neurodegenerative disorders.

The GPCR signaling pathway is a critical regulatory system that plays a crucial role in many cellular processes. It is involved in the regulation of various physiological processes, including neuronal communication, inflammation, and stress response. GADD45A is a key component of this pathway, as it functions as a scaffold protein that helps to regulate the activity of GPCRs.

GADD45A is a 45kDa protein that is expressed in various tissues and cells. It is highly conserved, with a calculated pI of 11.12, and is located in the endoplasmic reticulum (ER) and cytoplasm. GADD45A is involved in the regulation of several cellular processes, including cell signaling, cytoskeletal organization, and stress response.

One of the unique features of GADD45A is its ability to interact with multiple GPCRs. This is achieved through its N-terminus, which contains a region of 199 amino acids that is involved in the interaction with GPCRs. The N-terminus of GADD45A contains several putative binding sites that are involved in the regulation of various cellular processes.

GADD45A has been identified as a potential drug target for several diseases, including mental health, addiction, and neurodegenerative disorders. For example, GADD45A has been shown to be involved in the regulation of dopamine release in response to various drugs, including nicotine and alcohol. Additionally, GADD45A has been shown to be involved in the regulation of ion channels, including the K+ channel, which is involved in neuronal communication.

GADD45A has also been identified as a potential biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and addiction. For example, GADD45A has been shown to be decreased in the brains of individuals with Alzheimer's disease, and has been shown to be involved in the regulation of neurotoxin exposure in response to environmental stressors, such as stress and smoking.

In conclusion, GADD45A is a highly conserved protein that is involved in the regulation of various cellular processes, including cell signaling and stress response. Its ability to interact with multiple GPCRs makes it a potential drug target and biomarker for a wide range of diseases. Further research is needed to fully understand the role of GADD45A in cellular processes and its potential as a drug target and biomarker.

Protein Name: Growth Arrest And DNA Damage Inducible Alpha

Functions: In T-cells, functions as a regulator of p38 MAPKs by inhibiting p88 phosphorylation and activity (By similarity). Might affect PCNA interaction with some CDK (cell division protein kinase) complexes; stimulates DNA excision repair in vitro and inhibits entry of cells into S phase

The "GADD45A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GADD45A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets